Evaluating the effectiveness of deucravacitinib for plaque psoriasis in adults in France

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess how effective deucravacitinib is in treating adults with moderate-to-severe plaque psoriasis in real-world settings. Participants will be adults aged 18 and older who are newly starting treatment with deucravacitinib, as reported by their physicians. The study will gather data on treatment outcomes and patient experiences to better understand the drug's effectiveness outside of controlled clinical environments.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ≥18 years of age
* Physician-reported diagnosis of moderate to severe plaque psoriasis
* Be newly initiating deucravacitinib
* Do not object to participate

Exclusion Criteria:

* Currently participating in or planning to participate in an interventional clinical trial
* Previous treatment experience with deucravacitinib, including patients who received deucravacitinib as part of a blinded, randomized trial

Where it's running

• Chu Amiens Picardie - Site Sud
  Amiens, France Recruiting
• Cabinet Médical Elisabeth Lion
  Angers, France Recruiting
• Ch Victor Dupouy
  Argenteuil, France Recruiting
• Ch Arras
  Arras, France Recruiting
• Cabinet Dermatologie
  Bordeaux, France Recruiting
• Cabinet Dermatologie
  Bordeaux, France Recruiting

Study contacts

• Study coordinator: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
• Email: Clinical.Trials@bms.com
• Phone: 855-907-3286

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing the effectiveness of two medications for plaque psoriasis

  This study is testing whether deucravacitinib or apremilast works better for adults with plaque psoriasis who are starting treatment.

  Recruiting Bristol-Myers Squibb · Waltham, Massachusetts · NCT05744466

• HB0017 Injection safety and PK in low-weight adults at different injection sites

  This early-phase study tests a single subcutaneous HB0017 injection in healthy, low-weight adults and compares how the body processes the drug when injected at different sites.

  Recruiting Phase 1 Huabo Biopharm Co., Ltd. · Hangzhou, Zhejiang · NCT07920861

• MK-8644: first-in-human test in healthy people and people with psoriasis

  This early-phase study tests MK-8644 versus placebo in healthy volunteers and people with psoriasis to see if it is safe and tolerable.

  Recruiting Phase 1 Merck Sharp & Dohme LLC · Melbourne, Victoria · NCT07850310

• Is XJH05 Ointment Effective for Plaque Psoriasis?

  This study tests whether the XJH05 ointment can help people with plaque psoriasis compare to a calcipotriol ointment.

  Recruiting Xijing Hospital · Xi'an, Shaanxi · NCT07780929

• Guselkumab after Ustekinumab in adults with moderate-to-severe psoriasis in routine care

  This study looks at how well guselkumab works for people with moderate-to-severe psoriasis after switching from ustekinumab in everyday clinical practice.

  Recruiting Janssen-Cilag Kft. · Budapest · NCT07746583

• TQH3906 capsules vs warmer options in adults with moderate to severe plaque psoriasis

  This Phase 3 trial tests whether once-daily TQH3906 capsules can help adults with moderate to severe plaque psoriasis better than a placebo or the active drug deucravacitinib.

  Recruiting at 13 sites Phase 3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality and 44 other locations · NCT07724366

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.